Stimulation of the B-cell receptor (BCR) in CLL cells leads to phosphorylation of STAT3, indicating STAT3 as a novel target for therapeutic intervention in CLL [10]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.